Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Next Previous
X
Search
Trial Profile

A Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PH 284 (Primary)
  • Indications Cachexia
  • Focus Therapeutic Use
  • Sponsors Pherin Pharmaceuticals

    • Most Recent Events

    • 28 Jan 2025 New trial record
    • 14 Jan 2025 According to a VistaGen Therapeutics media release, this trial was sponsored by Pherin Pharmaceuticals, now a wholly owned subsidiary of Vistagen, and conducted at the National Institute of Oncology and National Institute of Nutrition in Mexico City, Mexico, in 2005. Vistagen gained access to the results of this study in connection with its acquisition of Pherin in February 2023. Hector Burges, MD,Marcos Cano Guardiana, MD and Ricardo Plancarte Sanchez served as the Principal Investigators.
    • 14 Jan 2025 Results presented in the VistaGen Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top